[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Oncotelic Therapeutcs Inc (OTLC)

Oncotelic Therapeutcs Inc (OTLC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])

Fundamentals

See More
  • Market Capitalization, $K 26,351
  • Shares Outstanding, K 443,616
  • Annual Sales, $ 0 K
  • Annual Income, $ 249,280 K
  • EBIT $ -5 M
  • EBITDA $ -5 M
  • 60-Month Beta -0.54
  • Price/Sales N/A
  • Price/Cash Flow 0.11
  • Price/Book 0.10
  • Price/Earnings ttm 0.10
  • Earnings Per Share ttm 0.59
  • Most Recent Earnings $0.00 on 05/14/26
  • Next Earnings Date 08/12/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0350 +69.71%
on 05/06/26
0.0620 -4.19%
on 05/28/26
+0.0238 (+66.85%)
since 04/29/26
3-Month
0.0294 +102.04%
on 03/13/26
0.0620 -4.19%
on 05/28/26
+0.0130 (+28.02%)
since 02/27/26
52-Week
0.0150 +296.00%
on 02/11/26
0.1100 -46.00%
on 10/22/25
-0.0036 (-5.71%)
since 05/28/25

Most Recent Stories

More News
TechForce Robotics Enters Pharmaceutical Automation Market Through Initial Deployment at Oncotelic Therapeutics

Deployment of the Company's LIM-E autonomous laboratory support robot completes Phase 1 objectives under the joint development agreement and establishes a foundation for future pharmaceutical automation...

OTLC : 0.0594 (-2.30%)
NGTF : 0.0291 (+3.93%)
Sapu Nano Unveils Progress in Deciparticle™ Nanomedicine Platform and AI-Driven Oncology Development at BIO 2026

SAN DIEGO, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- via IBN -- Sapu Nano and Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) today announced that Vuong Trieu, Chief Executive Officer,...

OTLC : 0.0594 (-2.30%)
Oncotelic Therapeutics Files First Quarter 2026 Financial Results and Strategic Progress

Agoura Hills, Calif., May 15, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) (“Oncotelic” or the “Company”), a clinical-stage biotechnology company focused on oncology, AI-enabled...

OTLC : 0.0594 (-2.30%)
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Responds to BBB Challenge with Next-Gen Drug-Delivery Platform

NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- via BioMedWire -- Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands...

OTLC : 0.0594 (-2.30%)
Sapu Nano Announces First Patient Dosed in Phase 1b Trial of Sapu003, an Intravenous Deciparticle™ Formulation of Everolimus

SAN DIEGO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- via IBN -- Sapu Nano and Oncotelic (OTCQB: OTLC) today announced that the first patient has been dosed in the Phase 1b clinical trial of Sapu003, the...

OTLC : 0.0594 (-2.30%)
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Proprietary N2B System May Offer Key to Unlocking Next-Gen Therapies

NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- via BioMedWire -- Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands...

OTLC : 0.0594 (-2.30%)
Oncotelic Therapeutics Announces Closing of a Strategic Monetization of Its CNS/Nasal Assets with Lunai Bioworks, Advancing Joint Development in Biodefense and Alzheimer’s Disease

AGOURA HILLS, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- via IBN -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) (“Oncotelic” or the “Company”), a late-stage clinical biopharmaceutical company focused...

OTLC : 0.0594 (-2.30%)
Oncotelic Therapeutics Advances Toward Commercial Launch of AI-Enabled Robotics Platform Following Integration of 28 Million Scientific Abstracts

LOS ANGELES, April 30, 2026 (GLOBE NEWSWIRE) -- via IBN -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB: OTLC), a clinical-stage biotechnology company focused on oncology...

OTLC : 0.0594 (-2.30%)
Oncotelic Therapeutics Provides Corporate Update on Partnership Strategy

AGOURA HILLS, Calif., April 24, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases,...

OTLC : 0.0594 (-2.30%)
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Real-World Example of Scientific Advancement Influence on Evaluation

NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- via BioMedWire -- Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands...

OTLC : 0.0594 (-2.30%)

Business Summary

Mateon is a biopharmaceutical company focused on the modulation of transforming growth factor-beta (TGF-beta) for the treatment of cancer and infectious diseases, including COVID-19. The company's lead development compound, OT-101 (trabedersen), is a single stranded antisense oligonucleotide targeting...

See More

Key Turning Points

3rd Resistance Point 0.0658
2nd Resistance Point 0.0635
1st Resistance Point 0.0615
Last Price 0.0594
1st Support Level 0.0572
2nd Support Level 0.0549
3rd Support Level 0.0529

See More

52-Week High 0.1100
Fibonacci 61.8% 0.0737
Fibonacci 50% 0.0625
Last Price 0.0594
Fibonacci 38.2% 0.0513
52-Week Low 0.0150

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.